zur Navigation zum Inhalt

Onkologie

Liquid biopsy in the context of EGFR and other mutations

01/2017 Compared to tissue biopsy and re-biopsy, liquid biopsy offers several advantages, including minimal-invasiveness, the opportunity for serial measurements over time to monitor tumour response, and detection of resistance mutations in the plasma prior to radiographic detection [1]. [...]

Who is a candidate for immunotherapy?

01/2017 WHICH MARKERS ARE AVAILABLE THAT DEFINE PATIENTS WHO ARE SUITABLE FOR IMMUNOTHERAPY? When we look at immunotherapy for NSCLC, we should realize that approximately 20 % of treated patients show a response. To direct treatment to patients with a higher likelihood of response, biomarkers might be of value. [...]

Immunotherapy: novel anti-PD-L1 antibodies & various combination regimens

01/2017 OAK subgroup analyses

As compared to anti-PD-1 antibodies, the advantage of antibodies directed against PD-L1 is that they can inhibit PD-1/ PD-L1 interactions while leaving the PD-1/ PD-L2 pathway intact, thus potentially preserving peripheral immune homoeostasis. [...]

Anti-angiogenesis with nintedanib: activity in mesothelioma, and potential biomarkers

01/2017 LUME-Meso

Malignant pleural mesothelioma generally has poor patient prognosis, as it is often diagnosed at an advanced stage. The only approved regimen consists of the combination of pemetrexed and cisplatin, which gives rise to a median OS of approximately 1 year [1]. [...]

Acht Millionen Datenschätze

01/2017 Ursachenforschung. Ein neues mathematisches Modell ermöglicht einen „Index der Krankheitsursachen“. Heimische Forscher können feststellen, ob eine komplexe Krankheit genetisch oder rein umweltbedingt ist.

Patienten mit komplexen Krankheiten haben ein hohes Risiko, an einer weiteren zu erkranken. [...]

„Das Fünf-Jahres-Überleben wird der Prüfstein schlechthin sein“

01/2017 3 Fragen, 3 Antworten

Der Präsident des jüngsten Lungenkrebs-Weltkongresses in Wien betont, dass Nichtrauchen die beste Strategie im Kampf gegen Lungenkrebs ist.

_Ihre Kongress-Höhepunkte?_

Pirker:Einerseits der Bericht des Präsidenten von Uruguay (der Krebsspezialist Tabaré Vazquez, [...]

Medizin heute

Aktuelle Printausgaben

SCHWERPUNKTE ONKOLOGIE

I-O P-Z